January 9, 2014 – Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.
November 13, 2012 – Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.
June 7, 2012 – OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.
January 30, 2012 – Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.
May 3, 0206 – Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.